Clinical efficacy of tigrelol combined with levosimendan in patients with acute myocardial infarction after percutaneous coronary intervention
Objective To observe the therapeutic effect of tigrelol combined with levosimendan on patients with acute myocardial infarction(AMI)after percutaneous coronary intervention(PCI).Methods Totally 116 AMI patients were randomly assigned in 1∶1 ratio to receive tigrelol(control group)or tigrelol + levosimendan(observation group)before and after PCI.The platelet aggregation rate,cardiac index(CI),myocardial microcirculation parameters and major cardiovascular adverse events(MACE)were included as comparisons.Results Compared with before PCI treatment,the platelet aggregation rate was significantly lower and the levels of left ventricular ejection fraction(LVEF),CI and stroke volume index(SVI)was significantly higher in both groups on 1 week after PCI(all P<0.05).The levels of LVEF,CI and SVI in the observation group were significantly higher than those in the control group(P<0.05).Compared with before PCI treatment,perfusion time to the contrast agents(AT)and time to peak perfusion(APT)in myocardial infarction area were significantly higher,and peak intensity(PI)were significantly lower in both groups on 1 week after PCI;the above indexes in the observation group were superior to the control group(all P<0.05).There was no significant difference in the total incidence of MACE,non-fatal myocardial reinfarction,sudden cardiac death,and target vessel revascularization between groups within 30 days after PCI(P>0.05).Conclusion For AMI patients after PCI,ticagrelor can play a good anti-platelet aggregation function.However,the combination of ticagrelor and levosimendan was significantly better than ticagrelor alone in the recovery of cardiac function and myocardial microcirculation in spite of its unclear effect on reducing the MACE occurrence.
万方数据
维普
